Baloxavir Marboxil

Influenza, as one of the acute respiratory infectious diseases with the highest incidence rate globally, has long been faced with clinical pain points of drug resistance and narrow medication windows. The advent of baloxavir marboxil provides a brand-new path for anti-influenza treatment. As the first anti-influenza drug belonging to the CAP-dependent endonuclease inhibitor class, it exerts its effect by blocking the key early step of influenza virus replication. A single oral dose is sufficient to complete the full course of treatment. It is indicated for the treatment of influenza A and B in people aged 12 years and above, and can also be used for post-exposure prophylaxis. Compared with traditional neuraminidase inhibitors, it significantly improves patients' medication compliance.

Currently, the global market size of anti-influenza API is growing steadily. As a new generation of core variety, baloxavir marboxil's global related API market size had exceeded USD 120 million in 2023, with a compound annual growth rate remaining above 27%. In terms of the domestic market, as generic pharmaceutical companies accelerate their layout before the expiration of the original research patent in 2031, more than 15 enterprises had submitted marketing applications for generic baloxavir marboxil as of 2024. The demand for localized API continues to rise, and high-quality and compliant impurity reference standards have become the core rigid demand for pharmaceutical companies in R&D and declaration.

CATO can provide a full set of impurity reference standards for baloxavir marboxil API. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. With sufficient stock reserves, we can quickly respond to the testing demands of R&D and production ends, and help pharmaceutical companies shorten the declaration cycle and reduce quality research costs.